- Home
- NFLX vs ABBV Comparison
NFLX vs ABBV Comparison
Compare NFLX & ABBV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NFLX
- ABBV
- Stock Information
- Founded
- NFLX 1997
- ABBV 2012
- Country
- NFLX United States
- ABBV United States
- Employees
- NFLX N/A
- ABBV N/A
- Industry
- NFLX Consumer Electronics/Video Chains
- ABBV Biotechnology: Pharmaceutical Preparations
- Sector
- NFLX Consumer Discretionary
- ABBV Health Care
- Exchange
- NFLX Nasdaq
- ABBV Nasdaq
- Market Cap
- NFLX 429.1B
- ABBV 370.7B
- IPO Year
- NFLX 2002
- ABBV N/A
- Fundamental
- Price
- NFLX $928.90
- ABBV $208.85
- Analyst Decision
- NFLX Buy
- ABBV Strong Buy
- Analyst Count
- NFLX 32
- ABBV 21
- Target Price
- NFLX $1,025.41
- ABBV $212.70
- AVG Volume (30 Days)
- NFLX 5.5M
- ABBV 6.9M
- Earning Date
- NFLX 04-17-2025
- ABBV 04-25-2025
- Dividend Yield
- NFLX N/A
- ABBV 3.19%
- EPS Growth
- NFLX 64.84
- ABBV N/A
- EPS
- NFLX 19.83
- ABBV 2.39
- Revenue
- NFLX $39,000,966,000.00
- ABBV $56,334,000,000.00
- Revenue This Year
- NFLX $15.85
- ABBV $7.74
- Revenue Next Year
- NFLX $11.99
- ABBV $8.02
- P/E Ratio
- NFLX $47.09
- ABBV $85.90
- Revenue Growth
- NFLX 15.65
- ABBV 3.71
- 52 Week Low
- NFLX $542.01
- ABBV $153.58
- 52 Week High
- NFLX $1,064.50
- ABBV $218.66
- Technical
- Relative Strength Index (RSI)
- NFLX 45.30
- ABBV 55.77
- Support Level
- NFLX $966.32
- ABBV $196.49
- Resistance Level
- NFLX $998.70
- ABBV $215.50
- Average True Range (ATR)
- NFLX 29.13
- ABBV 4.61
- MACD
- NFLX 1.38
- ABBV -1.62
- Stochastic Oscillator
- NFLX 37.22
- ABBV 65.02
About NFLX Netflix Inc.
Netflix's relatively simple business model involves only one business, its streaming service. It has the biggest television entertainment subscriber base in both the United States and the collective international market, with more than 300 million subscribers globally. Netflix has exposure to nearly the entire global population outside of China. The firm has traditionally avoided a regular slate of live programming or sports content, instead focusing on on-demand access to episodic television, movies, and documentaries. The firm introduced ad-supported subscription plans in 2022, giving the firm exposure to the advertising market in addition to the subscription fees that have historically accounted for nearly all its revenue.
About ABBV AbbVie Inc.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).